Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06638996 · ClinicalTrials.gov registry record · NA
Acute Psychological and Physiological Effects of Cannabigerol
A NA study of No Disease or Condition is Being Studied, sponsored by Washington State University.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06638996: Recruiting NA study of No Disease or Condition is Being Studied, sponsored by Washington State University.
NCT06638996 is a NA study of No Disease or Condition is Being Studied that is actively recruiting participants, run by Washington State University. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06638996, a NA study of No Disease or Condition is Being Studied, is actively recruiting participants, sponsored by Washington State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the acute effects of cannabigerol (CBG) on various psychological (e.g., anxiety, stress, mood, memory, impairment, intoxication, side effects) and physiological (blood pressure, cortisol, heart rate variability, electrodermal activity, pain tolerance, temperature) outcomes. Further, potential side effects of CBG (sleepiness/fatigue, dry mouth/eyes, increased appetite, and dizziness nausea) will be assessed. As such, the study is focused on better understanding some of the potentially beneficial and detrimental effects of CBG on humans.
Primary Outcome
Anxiety will be assessed along a 0 to 10 rating scale at baseline (T0), \~40 minutes after ingesting placebo or CBG (T1), after the stress test (T2), and after the memory tests (T3). Change scores from baseline to each time point will be examined.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT CBG Intervention
- OTHER Placebo Intervention
Study Locations (1)
Washington
- Washington State University - Pullman Campus - Pullman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-10-28 |
| Est. Completion | 2026-10-31 |
| Phase | NA |
What NCT06638996 shows while recruiting
NCT06638996 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with No Disease or Condition is Being Studied appearing as the primary indexed condition, and to 2 interventions - of which CBG Intervention is the first listed.
NCT06638996 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06638996 about?
NCT06638996 is a clinical study titled "Acute Psychological and Physiological Effects of Cannabigerol". The purpose of this study is to examine the acute effects of cannabigerol (CBG) on various psychological (e.g., anxiety, stress, mood, memory, impairment, intoxication, side effects) and physiological (blood pressure, cortisol, heart rate variability, electrodermal activity, pain tolerance, temperat...
What is the current status of trial NCT06638996?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-10-28. Estimated completion is 2026-10-31.
What conditions does trial NCT06638996 study?
This clinical trial studies the following conditions: No Disease or Condition is Being Studied.
What interventions are being tested in trial NCT06638996?
The interventions under investigation include: CBG Intervention (DIETARY_SUPPLEMENT), Placebo Intervention (OTHER).
Who is sponsoring clinical trial NCT06638996?
This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06638996 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for No Disease or Condition is Being Studied
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06638996's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI